ClinicalTrials.gg
CompletedNCT07947004Updated Nov 18, 2026

Intravenous Dexamethasone in Post Dural Puncture Headache Prophylaxis

A Phase 2/3 interventional study of intravenous dexamethasone and Saline in Post-Dural Puncture Headache, Pain Management and Cesarean Birth, sponsored by Pain Medicine Department. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Pain Medicine Department · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Mar 2025, registered Sep 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Hundred patients undergoing caesarean section under spinal anaesthesia were included in the study. Patients in Group D were given intravenous dexamethasone while those in Group S were given intravenous saline (placebo). Incidence of post dural puncture headache, severity using likert scale as a measurement tool, was assessed along with changes in haemodynamics and blood glucose levels were noted.

02

Conditions studied

  • Post-Dural Puncture Headache
  • Pain Management
  • Cesarean Birth
03

In context

Post-Dural Puncture Headache

123 studies on the registry are indexed under Post-Dural Puncture Headache; 26 are open to participants now.

This study's enrollment of 100 is above the median of 80 across 80 interventional studies indexed under Post-Dural Puncture Headache.

Browse Post-Dural Puncture Headache studies →

Lead sponsor

Pain Medicine Department is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • primigravid singleton pregnant women scheduled for elective cesarean section under spinal anesthesia were recruited. Eligible participants met the following criteria: Term pregnancy (≥37 weeks of gestation), (ASA) physical status I or II, age between 18 and 40 years, (BMI) between 18.5 and 35 kg/m²

Exclusion criteria

Exclusion Criteria:

  • to spinal anesthesia (e.g., coagulopathy, infection at puncture site, or patient refusal), known to dexamethasone, pre-existing comorbidities (e.g., diabetes mellitus, renal dysfunction [creatinine >2 mg/dL], hepatic disease, cardiovascular or neurological disorders, seizure disorders), hypertension or pre-eclampsia (systolic BP >160 mmHg or \<90 mmHg), intrauterine growth restriction (IUGR) or known fetal anomalies, \<8 g/dL, history of post-cesarean migraine headaches.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Dexamethasone Group

    Intravenous dexamethasone

    Drug: intravenous dexamethasone

  • Placebo comparator
    Saline Group

    intravenous saline

    Drug: Saline

Interventions

06

What researchers measure

Primary outcomes

  1. incidence of post-dural puncture headache (PDPH)

    Proportion of participants who develop PDPH, assessed by a nurse at 24 and 48 hours after surgery. Headache is recorded as present or absent, with established PDPH defined as a headache score above the study threshold (VAS \>3).

    Time frame: PDPH assessments were performed at 24 and 48 hours postoperatively

Secondary outcomes

  1. Severity of post-dural puncture headache

    Headache severity assessed by a nurse at 24 and 48 hours after surgery using a 4-point Likert scale: 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain. Higher scores indicate worse headache.

    Time frame: assessed 24 hours and 48 hours postoperatively

  2. intraoperative mean heart rate

    Mean heart rate (beats per minute) recorded by standard monitoring during surgery and averaged over the intraoperative period.

    Time frame: from skin incision to end of surgery that is skin closure

Other outcomes

  1. Postoperative blood glucose level

    blood glucose concentration (mg/dL) measured at 24 hours after surgery.

    Time frame: at 24 hours postoperatively

07

Study locations

1 site
  • CMH Lahore Cantt
    Lahore, Punjab Province, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Sep 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Nov 18, 2026
StartActual
Mar 1, 2025
Primary completionActual
Sep 30, 2025
CompletionActual
Dec 31, 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947004
Lead sponsor
Pain Medicine Department
Responsible party
Moazzam Ali (Dr Moazzam Ali, Pain Medicine Department) — Principal investigator
First posted
Nov 18, 2026
Start date
Mar 1, 2025
Primary completion
Sep 30, 2025
Completion
Dec 31, 2025
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion